{"id":5132,"date":"2026-04-07T07:55:06","date_gmt":"2026-04-07T07:55:06","guid":{"rendered":"https:\/\/samer-choucair.com\/%d8%b3%d8%a7%d9%85%d8%b1-%d8%b4%d9%82%d9%8a%d8%b1-%d9%81%d9%88%d9%86%d8%af%d8%a7%d9%8a%d9%88-%d9%84%d9%8a%d8%b3-%d8%af%d9%88%d8%a7%d8%a1%d9%8b-%d8%a8%d9%84-%d8%a8%d8%af%d8%a7%d9%8a%d8%a9-%d8%a7%d9%86\/"},"modified":"2026-04-12T10:45:35","modified_gmt":"2026-04-12T10:45:35","slug":"orforglipron-is-not-just-a-drug","status":"publish","type":"post","link":"https:\/\/samer-choucair.com\/ar\/orforglipron-is-not-just-a-drug\/","title":{"rendered":"Samer Choucair: Orforglipron Is Not Just a Drug, but the Beginning of an Economic Shift in the Obesity Market"},"content":{"rendered":"

Investment leader Samer Choucair<\/span><\/span> believes that what Eli Lilly<\/span><\/span> has announced with the approval of Orforglipron is not merely a medical breakthrough, but a pivotal turning point in one of the fastest-growing healthcare markets globally.<\/p>\n

The regulatory approval in April 2026 of the first once-daily oral GLP-1 pill\u2014without strict requirements related to food intake or timing\u2014opens the door to a fundamentally new phase in obesity treatment and reshapes the competitive and investment landscape in this sector.<\/p>\n

\n

The Real Challenge: Patient Adherence<\/strong><\/span><\/h2>\n

After more than fifteen years of observing this field, Choucair explains that the biggest challenge has never been the effectiveness of weight-loss drugs, but rather patient adherence<\/strong>.<\/p>\n

While weekly injections such as Zepbound and Wegovy have demonstrated strong results, they have remained both a psychological and practical barrier for many users.<\/p>\n

This is where Orforglipron becomes highly significant\u2014it transforms treatment from a complex medical process into a simple daily habit, potentially expanding the global user base dramatically.<\/p>\n

\n

How the Drug Works<\/strong><\/span><\/h2>\n

Choucair explained that the drug mimics satiety hormones, leading to:<\/p>\n

    \n
  • Reduced appetite<\/li>\n
  • Slower gastric emptying<\/li>\n
  • Improved blood sugar control<\/li>\n<\/ul>\n

    This integrated mechanism goes beyond weight loss, extending to reducing risks associated with cardiovascular and metabolic diseases.<\/p>\n

    In advanced clinical trials, the drug demonstrated the ability to achieve meaningful weight loss over a relatively long period, making it a practical option not only for starting treatment but also for maintaining it.<\/p>\n

    \n

    Effectiveness vs. Sustainability<\/strong><\/span><\/h2>\n

    Although its maximum weight-loss results may be slightly lower than injectable treatments, Choucair emphasizes that the true equation in this market is not just effectiveness\u2014but sustainability<\/strong>.<\/p>\n

    A treatment that patients adhere to for years may be more valuable than a highly effective one abandoned after a few months.<\/p>\n

    From this perspective, Orforglipron does not directly compete with injections but rather complements them, opening the market to an entirely new segment of users who were previously excluded.<\/p>\n

    \n

    Safety Profile<\/strong><\/span><\/h2>\n

    From a safety standpoint, side effects appear consistent with other drugs in the same class, mainly involving gastrointestinal issues such as nausea and diarrhea.<\/p>\n

    These effects are typically temporary and diminish over time, which enhances the drug\u2019s potential for widespread adoption, especially with lower discontinuation rates compared to early trial phases.<\/p>\n

    \n

    The Bigger Picture: A Massive Investment Opportunity<\/strong><\/span><\/h2>\n

    According to Choucair, the real significance lies in the investment dimension.<\/p>\n

    The obesity drug market is no longer a niche segment\u2014it has evolved into a global competitive arena valued at tens of billions of dollars<\/strong>, with projections exceeding $100 billion in the coming years<\/strong>.<\/p>\n

    This growth is driven by:<\/p>\n

      \n
    • Rising global obesity rates<\/li>\n
    • A shift in medical perception, recognizing obesity as a chronic condition requiring long-term treatment<\/li>\n<\/ul>\n
      \n

      Competitive Landscape<\/strong><\/span><\/h2>\n

      In this context, Eli Lilly stands out as one of the biggest beneficiaries of this transformation, having built an integrated ecosystem that includes both injections and oral treatments, giving it a strong strategic advantage.<\/p>\n

      Meanwhile, competitors such as Novo Nordisk<\/span><\/span> remain strong players, but the shift toward oral treatments introduces new challenges that could reshape market shares in the coming years.<\/p>\n

      \n

      Beyond Big Pharma: Broader Opportunities<\/strong><\/span><\/h2>\n

      Choucair notes that opportunities extend beyond major pharmaceutical companies to include:<\/p>\n

        \n
      • Emerging biotech firms developing next-generation multi-target therapies<\/li>\n
      • Sector-focused investment funds offering exposure to growth while mitigating risks<\/li>\n<\/ul>\n

        However, the sector remains sensitive to regulatory changes and pricing pressures, particularly as insurance coverage expands and cost-control measures intensify.<\/p>\n

        \n

        The Future: Integration, Not Competition<\/strong><\/span><\/h2>\n

        According to Choucair, the future will not be a battle between pills and injections, but rather an integration of both<\/strong>.<\/p>\n

          \n
        • Injections will remain the fastest and most powerful option for advanced cases<\/li>\n
        • Pills will play a crucial role in long-term maintenance and adherence<\/li>\n<\/ul>\n

          This hybrid model could expand the overall market rather than divide it, which explains the strong investor enthusiasm.<\/p>\n

          \n

          Conclusion: A Signal of What\u2019s Next<\/strong><\/span><\/h2>\n

          Samer Choucair concludes that Orforglipron is not just a new drug, but a signal of a new phase where treatment convenience intersects with investment opportunity.<\/p>\n

          As the market expands and demand rises, those who recognize this shift early may position themselves ahead in one of the most significant growth waves in modern healthcare.<\/p>\n","protected":false},"excerpt":{"rendered":"

          Investment leader Samer Choucair believes that what Eli Lilly has announced with the approval of Orforglipron is not merely a medical breakthrough, but a pivotal turning point in one of the fastest-growing healthcare markets globally. The regulatory approval in April 2026 of the first once-daily oral GLP-1 pill\u2014without strict requirements related to food intake or […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-5132","post","type-post","status-publish","format-standard","hentry","category-market-insights-ar"],"acf":[],"_links":{"self":[{"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/posts\/5132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/comments?post=5132"}],"version-history":[{"count":2,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/posts\/5132\/revisions"}],"predecessor-version":[{"id":5136,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/posts\/5132\/revisions\/5136"}],"wp:attachment":[{"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/media?parent=5132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/categories?post=5132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/samer-choucair.com\/ar\/wp-json\/wp\/v2\/tags?post=5132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}